In active UC, upadacitinib induced and maintained remission

Geoffrey M. Forbes

doi:10.7326/J22-0073

In active UC, upadacitinib induced and maintained remission

Geoffrey M. Forbes

Internal Medicine

Research output: Contribution to journal › Article › peer-review

Abstract

SOURCE CITATION: Danese S, Vermeire S, Zhou W, et al. Upadacitinib as induction and maintenance therapy for moderately to severely active ulcerative colitis: results from three phase 3, multicentre, double-blind, randomised trials. Lancet. 2022;399:2113-28. 35644166.

Original language	English
Pages (from-to)	JC113
Journal	Annals of Internal Medicine
Volume	175
Issue number	10
DOIs	https://doi.org/10.7326/J22-0073
Publication status	Published - 1 Oct 2022

Access to Document

10.7326/J22-0073

Cite this

@article{7f475d4f5dee4fd093cc1ea48dcf574c,

title = "In active UC, upadacitinib induced and maintained remission",

abstract = "SOURCE CITATION: Danese S, Vermeire S, Zhou W, et al. Upadacitinib as induction and maintenance therapy for moderately to severely active ulcerative colitis: results from three phase 3, multicentre, double-blind, randomised trials. Lancet. 2022;399:2113-28. 35644166.",

author = "Forbes, {Geoffrey M.}",

year = "2022",

month = oct,

day = "1",

doi = "10.7326/J22-0073",

language = "English",

volume = "175",

pages = "JC113",

journal = "Annals of Internal Medicine",

issn = "0003-4819",

publisher = "American College of Physicians",

number = "10",

}

TY - JOUR

T1 - In active UC, upadacitinib induced and maintained remission

AU - Forbes, Geoffrey M.

PY - 2022/10/1

Y1 - 2022/10/1

N2 - SOURCE CITATION: Danese S, Vermeire S, Zhou W, et al. Upadacitinib as induction and maintenance therapy for moderately to severely active ulcerative colitis: results from three phase 3, multicentre, double-blind, randomised trials. Lancet. 2022;399:2113-28. 35644166.

AB - SOURCE CITATION: Danese S, Vermeire S, Zhou W, et al. Upadacitinib as induction and maintenance therapy for moderately to severely active ulcerative colitis: results from three phase 3, multicentre, double-blind, randomised trials. Lancet. 2022;399:2113-28. 35644166.

UR - http://www.scopus.com/inward/record.url?scp=85140275581&partnerID=8YFLogxK

U2 - 10.7326/J22-0073

DO - 10.7326/J22-0073

M3 - Article

C2 - 36191310

AN - SCOPUS:85140275581

SN - 0003-4819

VL - 175

SP - JC113

JO - Annals of Internal Medicine

JF - Annals of Internal Medicine

IS - 10

ER -

In active UC, upadacitinib induced and maintained remission

Abstract

Access to Document

Other files and links

Fingerprint

Cite this